Posted: 21 July 2025
Brandon BioCatalyst’s national biotech incubator, CUREator, has received a $33 million grant from the Australian Government’s Medical Research Future Fund (MRFF), bolstering support for early-stage therapeutic companies in both preclinical and clinical development. Through this funding, up to 15 biotech startups, each demonstrating high therapeutic and commercial promise, will receive non-dilutive grants of $1 million to $5 million to help advance their projects toward translation and commercialisation.
CUREator operates on a performance-based funding model, where tranches of capital are released contingent on achieving key development milestones. The program is overseen by an independent Investment Review Committee and benefits from guidance by an International Pharma Advisory Committee. CSIRO’s Biomedical Manufacturing division will augment this by offering technical support, training, and mentorship.
Dr Chris Nave, co-founder and CEO of Brandon BioCatalyst, underscored the impact of these investments:
“In just four years, CUREator and CUREator+ have deployed over $58 million in government funding to 57 biotech startups, unlocking more than $100 million in follow‑on investment and enabling 17 Australian clinical trials. Today’s grant enables us to continue to provide high‑potential teams with the capital, expertise and global connectivity they need to transform cutting‑edge science into therapies that improve lives.”
Brandon Capital’s venture leadership enhances CUREator’s framework by equipping participants with the commercial acumen required to attract talent, secure investment, and ultimately integrate into global markets. Recent successes include one exit (currently under embargo) and two FDA‑approved therapies, signalling strong momentum toward the close of their sixth venture fund.
This announcement confirms that applications for the next funding round will open later this year.
For more information click here.
